

Postgraduate Certificate

Rare

Gynecologic Tumors





Postgraduate Certificate

Rare Gynecologic Tumors

- » Modality: Online
- » Duration: 6 weeks
- » Certificate: TECH Global University
- » Accreditation: 7 ECTS
- » Schedule: at your own pace
- » Exams: online

Website: www.techitute.com/medicina/curso-universitario/tumores-ginecologicos-infrecuentes

Index

01

Introduction

p. 4

02

Objectives

p. 8

03

Course Management

p. 12

04

Structure and Content

p. 18

05

Methodology

p. 22

06

Certificate

p. 30

01

Introduction

Cases of genital cancer in women of reproductive age is becoming less and less of an exception. Advances in knowledge and treatments make continuous professional development essential in order to provide effective clinical care and guarantee patient safety. This program allows physicians to learn in a practical way.



A close-up photograph of a surgical field. A gloved finger is visible, holding a piece of tissue. The tissue is reddish and appears to be part of a larger mass. The background is a blue surgical drape.

“

New advances in gynecologic oncology drive us to develop new programs that meet the real needs of experienced professionals, so that they can incorporate new advances into their daily practice”

There are a variety of tumors in the female genital tract, which, due to their low incidence, are relatively unknown to professionals. The cure of these diseases is, therefore, dependent on appropriate professional development covering their management.

It is essential for specialist physicians to be up to date with the main issues relating to these Rare Gynecologic Tumors, since the wide-ranging advances that are constantly being made and published must be transferred to daily medical practice.

This program is aimed at providing the professional with that update.

This **Postgraduate Certificate in Rare Gynecologic Tumors** contains the most comprehensive and up-to-date scientific program on the market. Its most notable features are:

- ♦ The examination of clinical cases, presented by specialists in gynecologic oncology and other disciplines: The graphic, schematic, and practical contents with which they are created, provide scientific and practical information on the disciplines that are essential for professional practice
- ♦ An update on procedures for the management of rare gynecologic tumors
- ♦ Diagnostic and therapeutic techniques for rare gynecologic tumor pathology
- ♦ An algorithm-based interactive learning system for decision-making in the clinical situations presented throughout the course.
- ♦ All of this will be complemented by theoretical lessons, questions to the expert, debate forums on controversial topics, and individual reflection assignments.
- ♦ Content that is accessible from any fixed or portable device with an Internet connection



You will be able to learn about the most recent advances in the field of Rare Gynecologic Tumors, using the latest educational technology”

“

This Postgraduate Certificate is the best investment you can make when selecting a refresher program, for two reasons: in addition to updating your knowledge in Rare Gynecologic Tumors you will obtain a Postgraduate Certificate from TECH”

The teaching staff includes a team of leading gynecologists who bring their professional experience to this program, in addition to renowned specialists in other medical areas.

The multimedia content developed with the latest educational technology will provide the physician with situated and contextual learning, i.e., a simulated environment that will provide immersive training programmed to train in real situations.

The design of this program is based on Problem-Based Learning, by means of which the specialist must try to solve the different professional practice situations that arise throughout the program. To do this, you will be assisted by an innovative, interactive video system created by renowned and experienced experts in the field of gynecologic oncology with extensive teaching experience.

Incorporate the latest developments in the management of infrequent gynecological tumor processes into your medical practice and improve the prognosis of your patients.

It includes clinical cases and real images in high definition to bring clinical practice as close as possible to the development of the program.



02 Objectives

The main objective is to allow the incorporation of the latest advances in the approach to Rare Gynecologic Tumors, so that specialists can update their knowledge in a practical way, with the latest educational technology and adapting the educational process to their real needs.



“

This refresher program will provide you with the skills for confident decision making in the approach to Rare Gynecologic Tumors, and will help you grow professionally”




General Objective

- Update the specialist on treatments for rare gynecologic cancer, reviewing the molecular basis of carcinogenesis, its development and the production of metastasis in the affected patient.

“

Make the most of this opportunity and take the next step to get up to date on the latest developments in Rare Gynecologic Tumors”





Specific Objectives

- Recognize and understand the molecular bases of carcinogenesis as well as its development and metastasis production
- Define the basis of cellular growth regulation.
- Understand the role of carcinogens in the formation of genital cancer.
- Gain up-to-date knowledge of cancer genetics.
- Understand the cellular mechanisms of programmed cell death, apoptosis, their interaction with malignant pathology
- Interpret the mechanisms of cancer production and distant metastasis at a molecular level.
- Identify the origins of genetic alterations that provoke cancer.
- Identify the epigenetic changes and oncogenes related with genital tract tumor pathology
- Explain the mechanisms tumor neoformation in blood vessels.
- Recognize respiratory symptomatology, such as that caused by pleural effusion, in the treatment of gynecologic cancer.
- Identify the different types of less common genital tumors and the corresponding treatment and evolution.
- Revise the clinical manifestations and diagnosis of vaginal cancer.
- Review the different histological types and classify the different types of vaginal cancer.
- Evaluate and create an appropriate diagnostic and management plan for vaginal cancer.
- Establish the follow-up plan for vaginal cancer to be able to detect and recurrences.
- Identify the prognosis for each type of vaginal cancer.
- Review the epidemiology of gestational trophoblastic disease and the clinical features of hydatidiform mole.
- Study the clinical characteristic of gestational trophoblastic neoplasia.
- Appropriately evaluate the different forms of gestational trophoblastic disease with imaging techniques.
- Gain up-to-date knowledge of the histologic shapes of molar and invasive forms.
- Appropriately perform staging of placental invasive disease.
- Study the different types of surgical treatment suitable for treating the different forms of molar disease in pregnancy.
- Recognise and implement the most appropriate methods for follow-up treatment of molar disease in pregnancy.
- Appropriately classify the prognosis of gestational trophoblastic disease.
- Identify and assess the different tumors that can metastasize in the female genital tract.
- Study the way to deal with metastasized cancers in the genital tract.
- Analyze and treat neuroendocrine tumors in the female genital tract
- Review the way to deal with tumors of the rectovaginal septum, as well as symptomatology associated with gynecological tumors
- Evaluate the pain, the different types and the treatment of these types of tumors.
- Assess the presence of ascites in the context of gynecologic tumors in an appropriate way.
- Classify edema and manage it appropriately.
- Identify deep vein thrombosis and evaluate the most appropriate anticoagulant treatment for each case

03

Course Management

Including renowned international directors, all the content of this program is focused on the most current clinical practice. In this way, the specialist will have access to a privileged teaching content, enriched with a multitude of real examples and practical cases analyzed. In this way, the most outstanding advances in Gynecologic Oncology can be incorporated into daily practice, endorsed by recognized experts with multiple recognitions and accumulated clinical merits.





“

Get up-to-date with the latest advances in Gynecologic Oncology, supported by the experience of leading specialists in the field"

International Guest Director

A pioneer in the use of **CD8+ T Cells** as a therapeutic tool for various **Viral Infections**, Dr. Otto Yang is a prestigious **Physician** highly specialized in **Cellular Immunology**. In addition, he has led multiple **scientific research** projects that have laid the groundwork for the development of innovative therapies and even vaccines.

In this sense, he has worked in health institutions of international reference such as **UCLA Health** in California. In this way, his work has been focused on the creation and implementation of modern treatments to manage conditions related to **HIV, AIDS or cancer**. Thanks to this, he has driven advances in the design of personalized immunological treatments adapted to the specific needs of each patient. As a result, he has managed to optimize the **overall well-being** of numerous patients in the long term.

Moreover, he has been a key figure in the conduct of **clinical trials** related to **COVID-19**. As such, he has conducted a variety of comprehensive analyses to evaluate the effects of therapies such as **Remdesivir, Baricitinib** and even **Monoclonal Antibodies**. Such work has been essential to identify the most effective therapeutic options and improve informed clinical decision making on a global scale in the face of the SARS-CoV-2 outbreak.

Throughout its 40-year history, its clinical excellence has been rewarded on several occasions in the form of **awards**. An example of this is the award he received from the American Association of Immunologists for his **CAR-T therapies** for the treatment of **leukemias**. In his strong commitment to advancing healthcare, he has led a wide range of projects that have received more than 30 million dollars in funding. These achievements reflect his strategic leadership in generating cutting-edge solutions that bring tangible value to society.



Dr. Yang, Otto

- Chief of the Division of Infectious Diseases at UCLA Health in California, United States
- Founder and Chief Medical Officer of CDR3 Therapeutics, California
- Director of Scientific Research at AIDS Healthcare Foundation, Los Angeles, Los Angeles
- Research Scientist with over 170 published papers
- Scientific Director of Ozymia, Los Angeles
- HIV Physician at MCI-Cedar Junction, Massachusetts
- Infectious Diseases Internship at Harvard Medical School
- Internal Medicine Residency at Bellevue Hospital, New York
- M.D. from Brown University
- Member of: Board of Directors at California Applied Medicine and Frontida Electronic Health Records Software

“

Thanks to TECH, you will be able to learn with the best professionals in the world”

International Guest Director

As one of the pioneer surgeons in Brazil by introducing advanced techniques of **Laparoscopic Oncologic Surgery** in Paraná, Dr. Reitan Ribeiro is one of the most prolific figures in this specialty. So much so that he has even received recognition as an **honorary citizen** of the city of Curitiba, highlighting his work in the creation and development of the technique of **Uterine Transposition**.

The IJGC, International Journal of Gynecologic Cancer, has also recognized the outstanding work of Dr. Reitan Ribeiro. His publications on **Uterine Robotic Transposition in Cervical Cancer**, **Uterine Transposition after Radical Trachelectomy** and directed research in the technique of **Uterine Transposition** for patients with gynecological cancers who want to preserve fertility are highlighted. He has received the **national award for medical innovation** for his research in the field of **Uterine Transposition**, highlighting these advances in the preservation of the patient's fertility.

His professional career is not without success, as he holds **numerous positions of responsibility** in the prestigious Erasto Gaertner Hospital. He directs the research program in Gynecologic Oncology of this center, being also director of the Fellowship program in this specialty, in addition to coordinating the training program in Robotic Surgery focused on Gynecologic Oncology.

At the academic level, he has completed internships at numerous prestigious centers, including Memorial Sloan Kettering Cancer Center, McGill University and the National Cancer Institute of Brazil. He balances his clinical responsibilities with consulting work for leading medical and pharmaceutical companies, mainly Johnson & Johnson and Merck Sharp & Dohme.



Dr. Ribeiro, Reitan

- Research Director, Gynecologic Oncology Department - Erasto Gaertner Hospital - Brazil
- Director of the Fellowship Program in Gynecologic Oncology at the Erasto Gaertner Hospital.
- Director of the Robotic Surgery Training Program of the Gynecologic Oncology Department of the Erasto Gaertner Hospital.
- Senior Surgeon in the Department of Gynecologic Oncology, Erastus Gaertner Hospital.
- Director of the Resident Oncologist Program at the Erasto Gaertner Hospital.
- Consultant at Johnson & Johnson and Merck Sharp & Dohme
- Degree in Medicine at the Federal University of Porto Alegre
- Fellowship in Gynecologic Oncologic Surgery at Memorial Sloan Kettering Cancer Center
- Fellowship in Minimally Invasive Surgery, McGill University
- Internships at Governador Celso Ramos Hospital, National Cancer Institute of Brazil and Erasto Gaertner Hospital.
- Certification in Oncologic Surgery by the Oncologic Surgery Society of Brazil.



Thanks to TECH you will be able to learn with the best professionals in the world"

04

Structure and Content

The syllabus has been designed by a team of professionals who are aware of the importance of up-to-date medical education on the approach to rare gynecologic tumors, and are committed to excellent teaching using new educational technologies.



“

This Postgraduate Certificate in Rare Gynecologic Tumors contains the most comprehensive and up-to-date scientific program on the market”

Module 1. Biological Basis of Cancer

- 1.1. Cell Growth Regulation
- 1.2. Carcinogenesis and Carcinogens
- 1.3. Genetics of Cancer
- 1.4. Mechanisms of Apoptosis and Programmed Cell Death
- 1.5. Molecular Mechanisms of Cancer Production and Metastasis
- 1.6. Origin of Genetic Alterations
- 1.7. Epigenetic Changes and Oncogenes
- 1.8. Angiogenesis

Module 2. Uncommon Gynecologic Tumors

- 2.1. Vagina Cancer
 - 2.1.1. Introduction
 - 2.1.2. Clinical Manifestations
 - 2.1.3. Diagnosis
 - 2.1.4. Pathologic Anatomy
 - 2.1.4.1. Squamous Carcinoma
 - 2.1.4.2. Adenocarcinoma
 - 2.1.4.3. Sarcoma
 - 2.1.4.4. Melanoma
 - 2.1.5. Tumor Staging
 - 2.1.6. Treatment of Disease
 - 2.1.6.1. Surgery
 - 2.1.6.2. Radiotherapy
 - 2.1.6.3. Treatment Complications
 - 2.1.7. Monitoring
 - 2.1.8. Prognosis

- 2.2. Gestational Trophoblastic Disease
 - 2.2.1. Introduction and Epidemiology
 - 2.2.2. Clinical Forms
 - 2.2.2.1. Hydatidiform Mole
 - 2.2.2.1.1. Complete Hydatidiform Mole
 - 2.2.2.1.2. Partial Hydatidiform Mole
 - 2.2.2.2. Gestational Trophoblastic Neoplasm
 - 2.2.2.2.1. After Molar Pregnancy
 - 2.2.2.2.1.1. Persistent Gestational Trophoblastic Neoplasm
 - 2.2.2.2.2. After Non-Molar Pregnancy
 - 2.2.2.2.2.1. Choriocarcinoma
 - 2.2.2.2.2.2. Placental Site Trophoblastic Tumor
- 2.2.3. Diagnosis
 - 2.2.3.1. Human Chorionic Gonadotropin
 - 2.2.3.2. Ultrasound Study
 - 2.2.3.2.1. Complete Mole
 - 2.2.3.2.2. Partial Mole
 - 2.2.3.2.3. Invasive Mole
 - 2.2.3.2.4. Choriocarcinoma and Placental Site Tumor
 - 2.2.3.3. Other Imaging Techniques
- 2.2.4. Pathologic Anatomy
 - 2.2.4.1. Hydatidiform Mole
 - 2.2.4.1.1. Complete Mole
 - 2.2.4.1.2. Partial Mole
 - 2.2.4.2. Invasive Mole
 - 2.2.4.3. Choriocarcinoma
 - 2.2.4.4. Placental Site Trophoblastic Tumor
 - 2.2.4.5. Epithelioid Trophoblastic Tumor
- 2.2.5. Staging

- 2.2.6. Treatment
 - 2.2.6.1. Chemotherapy
 - 2.2.6.1.1. Low Risk Disease
 - 2.2.6.1.2. High Risk Disease and Metastasis
 - 2.2.6.1.3. Chemoresistant Disease
 - 2.2.6.2. Surgery
 - 2.2.6.2.1. Molar Evacuation
 - 2.2.6.2.2. Hysterectomy
 - 2.2.6.2.3. Myometrial Resection
 - 2.2.6.2.4. Pulmonary Resection
 - 2.2.6.2.5. Craniotomy
 - 2.2.6.2.6. Other Surgical Procedures
 - 2.2.6.2.7. Selective Arterial Embolization
- 2.2.7. Post-Treatment Monitoring
 - 2.2.7.1. Monitoring after Molar Evacuation
 - 2.2.7.2. Monitoring after Gestational Neoplasm Treatment
- 2.2.8. Prognosis
- 2.3. Metastatic Tumor in the Genital Tract
 - 2.3.1. Introduction
 - 2.3.2. Clinical Manifestations
 - 2.3.2.1. Secondary Tumors in the Uterine Body or Cervix
 - 2.3.2.2.1. From Genital or Pelvic Organs
 - 2.3.2.2.2. From Extragenital or Pelvic Organs
 - 2.3.2.2. Secondary Tumors in the Vagina
 - 2.3.2.3. Secondary Tumors on the Vulva
 - 2.3.2.4. Secondary Tumors in the Ovaries
 - 2.3.3. Diagnosis
 - 2.3.4. Pathologic Anatomy
 - 2.3.4.1. Gastrointestinal Tumors
 - 2.3.4.1.1. Metastasis of Intestinal Cancer
 - 2.3.4.1.2. Krukenberg Tumor
 - 2.3.4.2. Ovarian Lymphoma
 - 2.3.5. Treatment and Prognosis
- 2.4. Neuroendocrine Tumors
 - 2.4.1. Introduction
 - 2.4.2. Pathologic Anatomy
 - 2.4.2.1. Well-Differentiated Tumors
 - 2.4.2.2. Poorly-Differentiated Tumors
 - 2.4.3. Clinical Manifestations and Diagnosis
 - 2.4.3.1. Small Cell Tumor in the Vulva and Vagina
 - 2.4.3.2. Small Cell Tumor in the Uterus
 - 2.4.3.3. Neuroendocrine Tumors in the Cervix
 - 2.4.3.3.1. Small Cell Neuroendocrine Carcinoma
 - 2.4.3.3.2. Carcinoma neuroendocrino células grandes
 - 2.4.3.4. Ovarian, Fallopian Tube and Wide Ligament Tumor
 - 2.4.3.4.1. Ovarian Carcinoid
 - 2.4.3.4.1.1. Insular Carcinoid
 - 2.4.3.4.1.2. Trabecular Carcinoid
 - 2.4.3.4.1.3. Mucinous Carcinoid
 - 2.4.3.4.1.4. Strumal Carcinoid
 - 2.4.3.4.2. Small Cell Lung Type
 - 2.4.3.4.3. Undifferentiated Non-Small Cell Carcinoma
 - 2.4.4. Treatment
 - 2.4.5. Monitoring
 - 2.4.6. Prognosis
- 2.5. Rectovaginal Septum Tumors

05 Methodology

This program offers students a different way of learning. Our methodology uses a cyclical learning approach: **Relearning**.

This teaching system is used, for example, in the most prestigious medical schools in the world, and major publications such as the **New England Journal of Medicine** have considered it to be one of the most effective.



“

Discover Relearning, a system that abandons conventional linear learning, to take you through cyclical teaching systems: a way of learning that has proven to be extremely effective, especially in subjects that require memorization”

At TECH, we use the Case Method

What should a professional do in a given situation? Throughout the program, students will face multiple simulated clinical cases, based on real patients, in which they will have to do research, establish hypotheses, and ultimately resolve the situation. There is an abundance of scientific evidence on the effectiveness of the method. Specialists learn better, faster, and more sustainably over time.

With TECH you will experience a way of learning that is shaking the foundations of traditional universities around the world.



According to Dr. Gervas, the clinical case is the annotated presentation of a patient, or group of patients, which becomes a “case”, an example or model that illustrates some peculiar clinical component, either because of its teaching power or because of its uniqueness or rarity. It is essential that the case is based on current professional life, trying to recreate the real conditions in the physician’s professional practice.

“

Did you know that this method was developed in 1912, at Harvard, for law students? The case method consisted of presenting students with real-life, complex situations for them to make decisions and justify their decisions on how to solve them. In 1924, Harvard adopted it as a standard teaching method.

The effectiveness of the method is justified by four fundamental achievements:

1. Students who follow this method not only achieve the assimilation of concepts, but also a development of their mental capacity, through exercises that assess real situations and the application of knowledge.
2. Learning is solidly translated into practical skills that allow the student to better integrate into the real world.
3. Ideas and concepts are understood more efficiently, given that the example situations are based on real-life.
4. Students like to feel that the effort they put into their studies is worthwhile. This then translates into a greater interest in learning and more time dedicated to working on the course.



Relearning Methodology

TECH effectively combines the Case Study methodology with a 100% online learning system based on repetition, which combines 8 different teaching elements in each lesson.

We enhance the Case Study with the best 100% online teaching method: Relearning.

Professionals will learn through real cases and by resolving complex situations in simulated learning environments. These simulations are developed using state-of-the-art software to facilitate immersive learning.



At the forefront of world teaching, the Relearning method has managed to improve the overall satisfaction levels of professionals who complete their studies, with respect to the quality indicators of the best online university (Columbia University).

With this methodology, more than 250,000 physicians have been prepared with unprecedented success in all clinical specialties regardless of surgical load. Our educational methodology is developed in a highly competitive environment, with a university student body with a strong socioeconomic profile and an average age of 43.5 years old.

Relearning will allow you to learn with less effort and better performance, involving you more in your specialization, developing a critical mindset, defending arguments, and contrasting opinions: a direct equation to success.

In our program, learning is not a linear process, but rather a spiral (learn, unlearn, forget, and re-learn). Therefore, we combine each of these elements concentrically.

The overall score obtained by TECH's learning system is 8.01, according to the highest international standards.

This program offers the best educational material, prepared with professionals in mind:



Study Material

All teaching material is produced by the specialists who teach the course, specifically for the course, so that the teaching content is highly specific and precise.

These contents are then adapted in audiovisual format, to create the TECH online working method. All this, with the latest techniques that offer high-quality pieces in each and every one of the materials that are made available to the student.



Surgical Techniques and Procedures on Video

TECH introduces students to the latest techniques, the latest educational advances and to the forefront of current medical techniques. All of this in direct contact with students and explained in detail so as to aid their assimilation and understanding. And best of all, you can watch the videos as many times as you like.



Interactive Summaries

The TECH team presents the contents attractively and dynamically in multimedia lessons that include audio, videos, images, diagrams, and concept maps in order to reinforce knowledge.


This exclusive educational system for presenting multimedia content was awarded by Microsoft as a "European Success Story".



Additional Reading

Recent articles, consensus documents and international guidelines, among others. In TECH's virtual library, students will have access to everything they need to complete their course.





06 Certificate

The Postgraduate Certificate in Rare Gynecologic Tumors guarantees students, in addition to the most rigorous and up-to-date education, access to a Postgraduate Certificate diploma issued by TECH Global University.



“

*Successfully complete this program
and receive your university qualification
without having to travel or fill out laborious
paperwork"*

This program will allow you to obtain a **Postgraduate Certificate in Rare Gynecologic Tumors** endorsed by **TECH Global University**, the world's largest online university.

TECH Global University, is an official European University publicly recognized by the Government of Andorra (**official bulletin**). Andorra is part of the European Higher Education Area (EHEA) since 2003. The EHEA is an initiative promoted by the European Union that aims to organize the international training framework and harmonize the higher education systems of the member countries of this space. The project promotes common values, the implementation of collaborative tools and strengthening its quality assurance mechanisms to enhance collaboration and mobility among students, researchers and academics.

This **TECH Global University title**, is a European program of continuing education and professional updating that guarantees the acquisition of competencies in its area of knowledge, providing a high curricular value to the student who completes the program.

Title: **Postgraduate Certificate in Rare Gynecologic Tumors**

Modality: **Online**

Accreditation: **7 ECTS**

Official N° of Hours: **175 hours**.





Postgraduate Certificate

Rare Gynecologic Tumors

- » Modality: Online
- » Duration: 6 weeks
- » Certificate: TECH Global University
- » Accreditation: 7 ECTS
- » Schedule: at your own pace
- » Exams: online

Postgraduate Certificate

Rare

Gynecologic Tumors

